243 related articles for article (PubMed ID: 27758885)
1. Alternative Polyadenylation in Triple-Negative Breast Tumors Allows NRAS and c-JUN to Bypass PUMILIO Posttranscriptional Regulation.
Miles WO; Lembo A; Volorio A; Brachtel E; Tian B; Sgroi D; Provero P; Dyson N
Cancer Res; 2016 Dec; 76(24):7231-7241. PubMed ID: 27758885
[TBL] [Abstract][Full Text] [Related]
2. Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers.
Wang L; Lang GT; Xue MZ; Yang L; Chen L; Yao L; Li XG; Wang P; Hu X; Shao ZM
Theranostics; 2020; 10(23):10531-10547. PubMed ID: 32929364
[No Abstract] [Full Text] [Related]
3. Genome-wide profiling of AP-1-regulated transcription provides insights into the invasiveness of triple-negative breast cancer.
Zhao C; Qiao Y; Jonsson P; Wang J; Xu L; Rouhi P; Sinha I; Cao Y; Williams C; Dahlman-Wright K
Cancer Res; 2014 Jul; 74(14):3983-94. PubMed ID: 24830720
[TBL] [Abstract][Full Text] [Related]
4. 3'UTR shortening and EGF signaling: implications for breast cancer.
Akman HB; Oyken M; Tuncer T; Can T; Erson-Bensan AE
Hum Mol Genet; 2015 Dec; 24(24):6910-20. PubMed ID: 26395459
[TBL] [Abstract][Full Text] [Related]
5. Recurrent tumor-specific regulation of alternative polyadenylation of cancer-related genes.
Xue Z; Warren RL; Gibb EA; MacMillan D; Wong J; Chiu R; Hammond SA; Yang C; Nip KM; Ennis CA; Hahn A; Reynolds S; Birol I
BMC Genomics; 2018 Jul; 19(1):536. PubMed ID: 30005633
[TBL] [Abstract][Full Text] [Related]
6. Alternative polyadenylation of single cells delineates cell types and serves as a prognostic marker in early stage breast cancer.
Kim N; Chung W; Eum HH; Lee HO; Park WY
PLoS One; 2019; 14(5):e0217196. PubMed ID: 31100099
[TBL] [Abstract][Full Text] [Related]
7. The microRNA target site landscape is a novel molecular feature associating alternative polyadenylation with immune evasion activity in breast cancer.
Kim S; Bai Y; Fan Z; Diergaarde B; Tseng GC; Park HJ
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32844230
[TBL] [Abstract][Full Text] [Related]
8. AP-1 Is a Key Regulator of Proinflammatory Cytokine TNFα-mediated Triple-negative Breast Cancer Progression.
Qiao Y; He H; Jonsson P; Sinha I; Zhao C; Dahlman-Wright K
J Biol Chem; 2016 Mar; 291(10):5068-79. PubMed ID: 26792858
[TBL] [Abstract][Full Text] [Related]
9. Aberrant Alternative Polyadenylation is Responsible for Survivin Up-regulation in Ovarian Cancer.
He XJ; Zhang Q; Ma LP; Li N; Chang XH; Zhang YJ
Chin Med J (Engl); 2016 May; 129(10):1140-6. PubMed ID: 27174320
[TBL] [Abstract][Full Text] [Related]
10. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
11. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer.
Phan B; Majid S; Ursu S; de Semir D; Nosrati M; Bezrookove V; Kashani-Sabet M; Dar AA
Oncotarget; 2016 Apr; 7(15):19519-30. PubMed ID: 26799586
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
13. Differential genome-wide profiling of alternative polyadenylation sites in nasopharyngeal carcinoma by high-throughput sequencing.
Xu YF; Li YQ; Liu N; He QM; Tang XR; Wen X; Yang XJ; Sun Y; Ma J; Tang LL
J Biomed Sci; 2018 Oct; 25(1):74. PubMed ID: 30352587
[TBL] [Abstract][Full Text] [Related]
14. Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.
Fkih M'hamed I; Privat M; Ponelle F; Penault-Llorca F; Kenani A; Bignon YJ
Cell Oncol (Dordr); 2015 Dec; 38(6):433-42. PubMed ID: 26392359
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of cathepsin S expression by HSP90 and 5-HT
Gautam J; Bae YK; Kim JA
Breast Cancer Res Treat; 2017 Jan; 161(1):29-40. PubMed ID: 27796714
[TBL] [Abstract][Full Text] [Related]
16. miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.
O'Brien K; Lowry MC; Corcoran C; Martinez VG; Daly M; Rani S; Gallagher WM; Radomski MW; MacLeod RA; O'Driscoll L
Oncotarget; 2015 Oct; 6(32):32774-89. PubMed ID: 26416415
[TBL] [Abstract][Full Text] [Related]
17. Implications of polyadenylation in health and disease.
Curinha A; Oliveira Braz S; Pereira-Castro I; Cruz A; Moreira A
Nucleus; 2014; 5(6):508-19. PubMed ID: 25484187
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs as regulatory elements in triple negative breast cancer.
Gyparaki MT; Basdra EK; Papavassiliou AG
Cancer Lett; 2014 Nov; 354(1):1-4. PubMed ID: 25107641
[TBL] [Abstract][Full Text] [Related]
19. Non-Specific Blocking of miR-17-5p Guide Strand in Triple Negative Breast Cancer Cells by Amplifying Passenger Strand Activity.
Jin YY; Andrade J; Wickstrom E
PLoS One; 2015; 10(12):e0142574. PubMed ID: 26629823
[TBL] [Abstract][Full Text] [Related]
20. RNA Binding Protein CELF2 Regulates Signal-Induced Alternative Polyadenylation by Competing with Enhancers of the Polyadenylation Machinery.
Chatrikhi R; Mallory MJ; Gazzara MR; Agosto LM; Zhu WS; Litterman AJ; Ansel KM; Lynch KW
Cell Rep; 2019 Sep; 28(11):2795-2806.e3. PubMed ID: 31509743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
